Maxxim asset sale
This article was originally published in The Gray Sheet
Executive Summary
Privately held Medline's acquisition of Maxxim Medical's med/surg business solidifies its number one and two positions in the exam glove and tray markets, respectively, the firm says. A joint proposal by Medline and private equity firm RoundTable Healthcare Partners beat out investment firm Lightyear in a Delaware bankruptcy court auction of Maxxim assets Oct. 27 (1"The Gray Sheet" Sept. 22, 2003, p. 20). Approved by the court Oct. 28, the proposal was valued at about $100 mil., Medline says. RoundTable gains Maxxim's Argon vascular access and pressure monitoring products business, including guidewires, catheters, needles and sheath introducers. No layoffs or facility closures are planned...
You may also be interested in...
Maxxim Sale To Lightyear Resolves Bankruptcy; Management Likely To Stay
Investment firm Lightyear Capital's acquisition of Maxxim Medical will strengthen the procedure tray manufacturer's balance sheet and enable it to emerge from bankruptcy proceedings largely intact, the company asserts
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.